Related Experiment Video
Updated: Sep 9, 2025
A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos
Published on: November 8, 2014
Phenotypic screening for new heart failure therapeutics: scalable animal modeling in zebrafish
1Department of Medicine, Mass General Brigham and Harvard Medical School, Boston, MA, USA.
Introduction:
Congestive heart failure (CHF) is a complex multi-organ syndrome representative of many chronic 'diseases,' and as such it has proven resistant to traditional cell-based drug discovery cannot readily be captured the relevant systemic biology. In vivo drug discovery screens offer unique opportunities to identify the initial dysfunction which ultimately drives heart failure (HF) and novel pathways modifying the cardiac response to injury.
Areas Covered:
In this review, the author discusses phenotype-driven screens which allow rigorous and unbiased approaches to the biological systems which underpin HF (PubMed search terms on 07/11/2025-heart failure, cardiomyopathy, zebrafish, screen, drug). The rationale for specific models of HF and the relevance of the zebrafish in screens for suppressors of HF is discussed. Central principles are detailed for the successful design and execution of phenotypic screens for HF modifiers. A major focus is the development of scalable HF assays in the zebrafish.
Expert Opinion:
In vivo phenotypic screening in the zebrafish is a reproducible approach to the identification of potent suppressors of complex multisystem disorders including different forms of HF. Design features associated with success are the rigor and human fidelity of the initial mechanistic modeling and quantitative screen endpoints.
Insights
Phenotype-driven screens using zebrafish offer a robust method for discovering new treatments for heart failure (HF). This in vivo approach effectively identifies pathways that can modify the cardiac response to injury and suppress complex HF symptoms.
Area of Science:
- Cardiovascular Research
- Drug Discovery
- Zebrafish Models
Background:
- Congestive heart failure (CHF) is a complex, multi-organ syndrome resistant to traditional cell-based drug discovery due to limitations in capturing systemic biology.
- In vivo drug discovery screens provide a unique opportunity to identify early dysfunctions driving heart failure (HF) and novel pathways affecting cardiac injury response.
Purpose of the Study:
- To review phenotype-driven screens for identifying suppressors of heart failure (HF).
- To discuss the rationale for specific HF models and the utility of zebrafish in drug screens for HF.
- To detail principles for designing and executing effective phenotypic screens for HF modifiers.
Main Methods:
- Phenotype-driven screens utilizing zebrafish models for heart failure (HF).
- Development of scalable HF assays in zebrafish.
- Rigorous mechanistic modeling and quantitative screen endpoints for in vivo phenotypic screening.
Main Results:
- In vivo phenotypic screening in zebrafish is a reproducible method for identifying potent suppressors of complex multisystem disorders, including various forms of HF.
- Successful screens require rigorous, human-fidelity mechanistic modeling and quantitative endpoints.
Conclusions:
- Phenotype-driven in vivo screening in zebrafish presents a powerful and reproducible strategy for discovering novel therapeutic targets and suppressors for heart failure (HF).
- The approach allows for the identification of systemic factors and pathways critical to HF development and progression.
